1211 related articles for article (PubMed ID: 22786509)
1. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies D; Sinn JKh; Lad SS; Leach MJ; Ross MJ
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007986. PubMed ID: 22786509
[TBL] [Abstract][Full Text] [Related]
2. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies D; Leach MJ; Perez Algorta G
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
[TBL] [Abstract][Full Text] [Related]
5. Methylphenidate for children and adolescents with autism spectrum disorder.
Sturman N; Deckx L; van Driel ML
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
[TBL] [Abstract][Full Text] [Related]
6. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
Castells X; Blanco-Silvente L; Cunill R
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
[TBL] [Abstract][Full Text] [Related]
7. Dietary interventions for multiple sclerosis-related outcomes.
Parks NE; Jackson-Tarlton CS; Vacchi L; Merdad R; Johnston BC
Cochrane Database Syst Rev; 2020 May; 5(5):CD004192. PubMed ID: 32428983
[TBL] [Abstract][Full Text] [Related]
8. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Punja S; Shamseer L; Hartling L; Urichuk L; Vandermeer B; Nikles J; Vohra S
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009996. PubMed ID: 26844979
[TBL] [Abstract][Full Text] [Related]
9. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Otasowie J; Castells X; Ehimare UP; Smith CH
Cochrane Database Syst Rev; 2014 Sep; (9):CD006997. PubMed ID: 25238582
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ; Storm MRO; Pereira Ribeiro J; Skoog M; Groth C; Callesen HE; Schaug JP; Darling Rasmussen P; Huus CL; Zwi M; Kirubakaran R; Simonsen E; Gluud C
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD009885. PubMed ID: 36971690
[TBL] [Abstract][Full Text] [Related]
11. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Epstein T; Patsopoulos NA; Weiser M
Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
13. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048
[TBL] [Abstract][Full Text] [Related]
14. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.
Zwi M; Jones H; Thorgaard C; York A; Dennis JA
Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD003018. PubMed ID: 22161373
[TBL] [Abstract][Full Text] [Related]
15. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years.
Storebø OJ; Elmose Andersen M; Skoog M; Joost Hansen S; Simonsen E; Pedersen N; Tendal B; Callesen HE; Faltinsen E; Gluud C
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008223. PubMed ID: 31222721
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acid supplementation for cystic fibrosis.
Watson H; Stackhouse C
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD002201. PubMed ID: 32275788
[TBL] [Abstract][Full Text] [Related]
17. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Boesen K; Paludan-Müller AS; Gøtzsche PC; Jørgensen KJ
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012857. PubMed ID: 35201607
[TBL] [Abstract][Full Text] [Related]
18. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.
Storebø OJ; Skoog M; Damm D; Thomsen PH; Simonsen E; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD008223. PubMed ID: 22161422
[TBL] [Abstract][Full Text] [Related]
19. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.
Verbeeck W; Bekkering GE; Van den Noortgate W; Kramers C
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009504. PubMed ID: 28965364
[TBL] [Abstract][Full Text] [Related]
20. Polyunsaturated fatty acid supplementation for drug-resistant epilepsy.
Sarmento Vasconcelos V; Macedo CR; de Souza Pedrosa A; Pereira Gomes Morais E; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011014. PubMed ID: 27536971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
